PK, Safety and Tolerability of Brivaracetam Muco-Adhesive Gels

  • Research type

    Research Study

  • Full title

    Open-Label, Single-Dose, Pilot Study to Compare the Pharmacokinetics, Safety, and Tolerability of Brivaracetam from a Range of Muco-Adhesive Gels and Orally-Dosed Solution in Healthy Volunteers

  • IRAS ID

    243832

  • Contact name

    Helene Kadima

  • Contact email

    Helene.Kadima@ucb.com

  • Sponsor organisation

    UCB Biopharma SPRL

  • Eudract number

    2018-000672-15

  • Duration of Study in the UK

    0 years, 3 months, 24 days

  • Research summary

    The Sponsor is developing a new formulation (recipe) of the already marketed medicine, brivaracetam (BRV). Brivaracetam is currently licensed for use in patients with partial-onset seizures with or without secondary generalization in epilepsy and is administered orally (tablet or solution) or intravenously (bolus or infusion).\n\nThe aim of this study is to develop a suitable buccal formulation (administered into the oral cavity [inner cheek or under the lip]) to take forward into clinical efficacy assessments in patients who suffer from epilepsy with acute repetitive seizures.\n\nThe study will consist of 2 groups (Group A and Group B), each involving up to 16 healthy male and female volunteers. In Group A, variants of gel formulations, in addition to 1 oral solution formulation (reference), will be tested over 6 periods. The precise intra-oral location of dose administration will also be investigated in one chosen gel formulation (based on data gathered from previous doses in Group A) as this will be given both inside the cheek and under the front lip. Once dosed, volunteers will remain in the clinical unit for 2 days for blood samples to be taken and safety assessments performed. \n\nIn group B a formulation selected from Group A will be tested over 4 periods. The formulation will be dosed at two dose levels to assess dose proportionality. The polymer composition will be altered in 1 period and dosing without massage will also be investigated. Once dosed, volunteers will remain in the clinical unit for 2 days for blood samples to be taken and safety assessments performed.\n\nThroughout the study inspections of the volunteer’s mouths will be made and volunteers will be asked about the taste of the new formulations in palatability questionnaires.

  • REC name

    Wales REC 2

  • REC reference

    18/WA/0340

  • Date of REC Opinion

    19 Oct 2018

  • REC opinion

    Further Information Favourable Opinion